KR900701826A - 프로버어신 - Google Patents

프로버어신

Info

Publication number
KR900701826A
KR900701826A KR1019900700053A KR900700053A KR900701826A KR 900701826 A KR900701826 A KR 900701826A KR 1019900700053 A KR1019900700053 A KR 1019900700053A KR 900700053 A KR900700053 A KR 900700053A KR 900701826 A KR900701826 A KR 900701826A
Authority
KR
South Korea
Prior art keywords
peptide
arg
lys
gly
phe
Prior art date
Application number
KR1019900700053A
Other languages
English (en)
Inventor
오오드야 타판
골드 스타인 기드온
해브너 조오지
Original Assignee
원본미기재
이뮤노바이올로지 리서취 인스티튜트, 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 이뮤노바이올로지 리서취 인스티튜트, 인코오퍼레이티드 filed Critical 원본미기재
Publication of KR900701826A publication Critical patent/KR900701826A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

프로버어신
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 소간으로 부터의 프로버어신의 정제된 분획의 광학말도를 나타내는 그래프도이다; 제2도는 프로버어신의 박층 크로마토그래피겔의 예시도이다: 제3도는 항-버어신항제(점)와 토끼혈청(사각형)의 다양한 역가의 광학밀도를 나타내는 그래프도이다.

Claims (12)

  1. 식 Phe-Phe-Trp-Lys-Tys-Lys-Pro-Arg-Lys-His-Gly-Gly-Arg-Arg 그의 유사체의 서열과 동일한 또는 실질적으로 동일한 아미노산 서열로 이루어지는 펩티드, 및 그의 약학적으로 허용가능한 산-부가염.
  2. 제1항에 있어서, 고상 또는 액상 화학합성법에 의하여 제조되는 것을 특징으로 하는 펩티드.
  3. 제1항에 있어서, 사람 간세포 또는 사람 골수세포로부터 선택된 포유동물 세포로부터 정제되는 것을 특징으로 하는 펩티드.
  4. 제1항에 있어서, 제조합 기법에 의해 제조되는 것을 특징으로 하는 펩티드.
  5. 제1항에 있이서, 약 1㎍/㎖농도에서 다우디 또는 MOPC-315 세포의 세포내 cGMP 상승을 유도하는 역치 환성을 특징으로 하는 펩티드.
  6. 서열 Phe-Phe-Trp-Lys-Tys-Lys-Pro-Arg-Lys-His-Gly-Gly-Arg-Arg 를 가지는 펩티드, 및 그의 약학적으로 허용가능한 산-부가염.
  7. 적당한 제어서열과 효력있게 결합된 식 Phe-Phe-Trp-Lys-Tys-Lys-Pro-Arg-Lys-His-Gly-Gly-Arg-Arg 과 동일한 또는 실질적으로 동일한 아미노산 서열로 이루어지는 펩티드를 코드화 하는 서열로 이루어지는 DNA 분자.
  8. 약학적으로 허용 가능한 체형중의 치료적으로 유효한 양의 제1항의 펩티드로 이루어지는 약학 조성물.
  9. 환자의 면역시스템 조절에 적당한 약학 조성들의 제조에 대한 제1항의 펩티드 또는 그의 염의 이용.
  10. 종양성장을 저해하기에 층분한 양의 성장호르몬의 방출을 저해하기에 적당한 약학조성물의 제조에 대한 제1항의 펩티드 또는 그의 염의 이용.
  11. 식. R1-Phe-Phe-(R2)Trp-(R3)Lys-(R4)Thr-(R5)Lys-Pro-(R|6)Arg-(R7)Lay-(R8)His-Gly-Gly-(R9)Arg-(R10)Arg 수지의 펩티드-수지 중간체로서 상기 식중 R1에서 R10은 각각 독립적으로 적절한 보호기로 부터 선택되고, 수지는 적절한 고체상 중합체인 것을 특징으로 하는 펩티드-수지 중간제.
  12. 제1항의 펩티드 또는 상기 펩티드에 대한 항체를 포함하는 진단시약.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700053A 1988-05-11 1989-05-08 프로버어신 KR900701826A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19248288A 1988-05-11 1988-05-11
US192,482 1988-05-11
US287,462 1988-12-20
US07/287,462 US4994554A (en) 1988-05-11 1988-12-20 Probursin
PCT/US1989/001962 WO1989010735A1 (en) 1988-05-11 1989-05-08 Probursin

Publications (1)

Publication Number Publication Date
KR900701826A true KR900701826A (ko) 1990-12-04

Family

ID=26888111

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700053A KR900701826A (ko) 1988-05-11 1989-05-08 프로버어신

Country Status (13)

Country Link
US (1) US4994554A (ko)
EP (1) EP0342015A3 (ko)
JP (1) JPH02504155A (ko)
KR (1) KR900701826A (ko)
CN (1) CN1037712A (ko)
AU (1) AU623148B2 (ko)
BR (1) BR8906960A (ko)
DK (1) DK6590A (ko)
HU (1) HU202885B (ko)
IL (1) IL90228A0 (ko)
NZ (1) NZ229003A (ko)
PT (1) PT90525A (ko)
WO (1) WO1989010735A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177405B1 (en) * 1992-07-22 2001-01-23 Kenji Nishioka Cyclic analogs of tuftsin
FR2801848B1 (fr) * 1999-12-01 2003-11-28 Pga Electronic Systeme de gestion des mouvements d'un ou de plusieurs sieges de vehicule

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291022A (en) * 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
US4190648A (en) * 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4584284A (en) * 1985-01-31 1986-04-22 Ortho Pharmaceutical Corporation Bursopoietin

Also Published As

Publication number Publication date
CN1037712A (zh) 1989-12-06
AU3688989A (en) 1989-11-29
DK6590D0 (da) 1990-01-10
IL90228A0 (en) 1989-12-15
BR8906960A (pt) 1990-11-20
EP0342015A2 (en) 1989-11-15
JPH02504155A (ja) 1990-11-29
WO1989010735A1 (en) 1989-11-16
HU202885B (en) 1991-04-29
US4994554A (en) 1991-02-19
EP0342015A3 (en) 1990-10-10
AU623148B2 (en) 1992-05-07
NZ229003A (en) 1992-01-29
HU893527D0 (en) 1990-11-28
HUT53913A (en) 1990-12-28
PT90525A (pt) 1989-11-30
DK6590A (da) 1990-01-10

Similar Documents

Publication Publication Date Title
Radu et al. Identification of a protein complex that is required for nuclear protein import and mediates docking of import substrate to distinct nucleoporins.
De Vroede et al. Modulation of insulinlike growth factor I binding to human fibroblast monolayer cultures by insulinlike growth factor carrier proteins released to the incubation media.
Mathews et al. Identity of the proliferating cell nuclear antigen and cyclin
Occhino et al. Isolation of an immunosuppressive peptide fraction from human plasma
KR880701288A (ko) M-csf의 제법
KR850003734A (ko) 고 정제 단백질의 제조방법
Chothia et al. Helix movements and the reconstruction of the haem pocket during the evolution of the cytochrome c family
JPH03201979A (ja) 安定性の高い組換えガンマインターフエロン
RU95113418A (ru) Полипептиды, способы получения, днк, вектор, клетка, применение полипептида, фармацевтические композиции
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
Fischer et al. An antiviral soluble form of the LDL receptor induced by interferon
KR890700610A (ko) 백혈병 억제 인자
CA2000048A1 (en) Peptides and antibodies that inhibit integrin-ligand bindin g
KR950704486A (ko) 성분b로 명명된 신규 단백질(new protein from urine named component b)
KR870009025A (ko) 재조합 숙주로부터 제조한 아프로티닌 동족체, 그의 방법, 표현 벡타 및 재조합 숙주 및 그의 재약상 용도
Timpl et al. Structure and biology of the globular domain of basement membrane type IV collagen
Herbert et al. Correction of COOH-terminal amino acids of human plasma very low density apolipoproteins
Pirollet et al. Purification and characterization of sheep brain cold-stable microtubules.
Vacquier Activation of sea urchin spermatozoa during fertilization
KR900003371A (ko) 재조합 천연 킬러 세포 활성화제
Michael et al. All eight unassigned reading frames of mouse mitochondrial DNA are expressed.
Otsuka et al. Structure, assembly, conformation, and immunological properties of the two subunit classes of ferritin
KR900701826A (ko) 프로버어신
Nakamura et al. Amino acid sequence of the peptide released from bovine factor XIII following activation by thrombin
Ben-Avram et al. Amino-terminal amino acid sequence of murine colony-stimulating factor 1.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid